SWISS-ADVANCED-VISION
SAV-IOL (Swiss Advanced Vision) is moving forward with the development of the R-TASC Project, the first electronic intraocular lens (IOL) with real-time autofocus, aimed to fully restore the vision post cataract surgery. R-TASC is set to push the boundaries of the Ophthalmic world within the next 5-7 years. SAV-IOL has already confirmed the technical feasibility of this project and is now seeking to raise USD 20M to bring this groundbreaking device to the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005336/en/
While the intraocular lens market is massive, there have been few sizeable innovations since they were first introduced. Moreover, present-day IOLs constantly suffer from optical compromises such as limited visual accommodation range, loss of light or unwanted visual disturbances. To break this barrier, SAV-IOL is looking at the situation from a different angle with a smart active lens. R-TASC is controlled electronically via a feedback loop mechanism made to control the curvature of the optic and therefore, adapt the power of the lens. “There is a level of trade-offs with all IOLs currently on the market,” said SAV-IOL’s CEO, Max Boysset. “R-TASC addresses the issues commonly associated with IOLs through an entirely novel approach.”
Standard IOLs are not able to fully substitute the optical properties of the natural lens and this is where R-TASC’s adaptative optical design provide an answer. In addition to completely restoring the visual accommodation, R-TASC enables patients and surgeons to calibrate the lens at any time after cataract surgery via an app-controlled system. The wirelessly platform of R-TASC is also future proofed to incorporate augmented reality and other interactive features, opening a whole new array of possibilities never seen before in the world of ophthalmology.
SAV-IOL will present the latest R-TASC prototype at the 37th Congress of the ESCRS in Paris in September 2019 (booth I123, pavilion 7) and at the MEDICA exhibition in Dusseldorf in November 2019 (Swiss Start-Ups Corner).
About SAV-IOL: SAV-IOL is a Swiss company that develops, manufactures, and markets EDOF IOLs. The portfolio of SAV-IOL is made of three products: Harmonis , a customizable EDOF IOL, Eden , a premium EDOF IOL, and Lucidis , an affordable EDOF IOL. SAV-IOL is ISO 13485:2016 certified (MD 615363) and the lenses are CE marked (CE 615365).
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905005336/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpZira, Inc. Launches to Advance Ophthalmic Diagnostics with Innovative Medical Device Portfolio3.9.2025 19:23:00 CEST | Press release
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced its official formation. OpZira is dedicated to delivering innovative technologies that enhance the detection and monitoring of ocular disease, empowering clinicians with advanced diagnostic tools. OpZira’s creation follows Alcon’s acquisition of LumiThera (https://www.alcon.com/media-release/alcon-completes-acquisition-lumithera/) and its innovative Valeda® Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD). As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc. OpZira’s product portfolio includes: AdaptDx Pro® – A wearable dark adaptometer that leverages AI to ensure a consistent patient experience. Impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the fir
BTG Bioliquids and NanosTech Partner to Deliver End-to-End Advanced Biofuels Solution3.9.2025 18:19:00 CEST | Press release
BTG Bioliquids BV (BTL), a Netherlands-based leader in fast pyrolysis technology, and NanosTech Technology & Innovations Ltd. (NanosTech), a Canada-based catalyst development and manufacturing company, have signed a Memorandum of Understanding (MOU) to deliver a fully integrated solution to produce advanced, drop-in biofuels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903698730/en/ The partnership combines BTL’s proven fast pyrolysis technology, which converts sustainable biomass into bio-oil, with NanosTech’s proprietary Aquaprocessing (AQP) platform, which upgrades even the most challenging bio-oils into refinery-ready feedstocks to produce fuels such as sustainable aviation fuel (SAF), renewable diesel, and marine fuels. The two companies are now actively collaborating to determine the location in Canada and Europe for the new 500-barrel-per-day modular biorefinery system. This system can be deployed near the feeds
Armis Named a Leader in IoT Security Solutions, Q3 2025 Evaluation3.9.2025 15:58:00 CEST | Press release
Recognition follows Armis being named a Leader in Unified Vulnerability Management Solutions evaluation Armis, the cyber exposure management & security company, today announced that it has been named a Leader in The Forrester Wave™: IoT Security Solutions, Q3 2025. This achievement comes on the heels of Armis being named a Leader in The Forrester Wave™: Unified Vulnerability Management Solutions, Q3 2025. In this Forrester Wave™, Armis is ranked a Leader and achieved the highest scores possible in 9 key criteria. According to the report, “Armis’ vision centers on delivering enterprise-wide exposure management that goes beyond IoT and OT devices. Its innovation investments and acquisitions support this goal. Its roadmap aligns with customer priorities while anticipating future needs to ensure the platform evolves alongside its clients. This forward-looking strategy fosters successful adoption and helps customers deploy the Centrix platform successfully.” “We’re proud to once again be re
Rapid Medical™ Surpasses 1,000 Cases With DRIVEWIRE™ 24 in North America and Expands Into Europe With MDR Approval3.9.2025 15:46:00 CEST | Press release
Clinical performance and strong physician demand drive swift uptake and global approval of next-generation access technology Rapid Medical™, a leading developer of active endovascular devices, announces that its DRIVEWIRE™ 24 steerable guidewire has been used in more than 1,000 neurovascular procedures in North America during a limited commercial launch beginning earlier this year. The company also announced receipt of CE Mark under the European Medical Device Regulation (MDR), as presented at the 2025 ESMINT Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903530140/en/ “In my experience, the wire provides a unique combination of precision and support that simply hasn’t been possible with conventional technologies,” stated Dr. Erez Nossek, a neurosurgeon at NYU Langone in New York, NY. “It has become a reliable tool that allows us to approach any anatomy with greater efficiency and less time.” As the first
Ondo Finance and Alpaca Collaborate to Tokenize US Stocks and ETFs3.9.2025 15:30:00 CEST | Press release
Bridging traditional finance and on-chain markets, increasing access to high-quality assets Today, Ondo Finance, a leader in blockchain-based financial innovation and tokenized real-world assets, announced the launch of Ondo Global Markets, their platform for tokenized US stocks and ETFs. The platform is powered by a strategic integration with Alpaca, a self-clearing broker-dealer and brokerage infrastructure API for stocks, ETFs, and options trading, as well as crypto. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903244835/en/ Ondo Finance and Alpaca collaborate to tokenize US stocks and ETFs; bridging traditional finance and on-chain markets, increasing access to high-quality assets. According to a McKinsey report, the tokenized market capitalization could reach around $2 trillion by 2030 across a variety of asset classes. This expected rise in market demand for tokenized assets, like US stocks and ETFs, comes as glob
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom